Эпилепсия и пароксизмальные состояния (Oct 2019)

Experimental study of the anticonvulsant and psychotropic activities of pufemid, pyrathidine, and compound N3212 as compared with reference anti-epileptic drugs

  • R. G. Paronikyan,
  • M. N. Avagyan,
  • A. A. Harutyunyan,
  • G. G. Avakyan,
  • S. A. Litvinova,
  • T. A. Voronina

DOI
https://doi.org/10.17749/2077-8333.2019.11.3.244-254.
Journal volume & issue
Vol. 11, no. 3
pp. 244 – 254

Abstract

Read online

Aim: to study the anticonvulsant and psychotropic activities and side effects of pufemid, pyrathidine and compound N3012 developed at the Institute of Fine Organic Chemistry of the National Academy of Sciences.Materials and methods. Anticonvulsant activities were tested using the following models of experimental seizures: maximum electric shock, corazol, camphor, thiosemicarbazide, picrotoxin, strychnine, amigdala-kindling convulsions. The psychotropic activities of the tested compounds were investigated using the “elevated plus maze”, “electroshock retrograde amnesia”, and the “open field” models. The neurotoxicity of the compounds was assessed by the level of impaired motor coordination in the “rotating rod” test and in the “grid climbing” test.Results. Pufemid, pyrathidine, and compound N3212 demonstrated high anticonvulsant activity that was superior to the reference antiepileptic drugs; in addition, the tested compounds had low toxicity and high indicators of therapeutic and protective effects. Pufemid, pyrathidine and compound N3212 showed psychotropic activities: e. g., compound N3212 had anxiolytic and nootropic effects.Conclusion. The tested compounds – pufemid, pyrathidine and compound N3212 – are highly efficient and low-toxic substances and are, therefore, promising for further preclinical and clinical studies as anti-epileptic drugs with psychotropic activities.

Keywords